GlaucomaDIOPSYSNCT03642782
Evaluation of the Electroretinogram Pattern (Diopsys® NOVA System) for the Early Diagnosis of Glaucoma
A study testing Electroretinogram Pattern (Diopsys® NOVA System) in people with Glaucoma, run by Fondation Hôpital Saint-Joseph at 1 site in France.
Trial summary
Glaucoma is a common and potentially blinding disease. It is characterized by an optic nerve damage, a visual field defect and elevated intraocular pressure (IOP). The loss of retinal nerve fibers is accompanied by functional impairment in the territories corresponding to deficits of the visual field. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glaucoma
- What is being tested?
- Electroretinogram Pattern (Diopsys® NOVA System)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteFrance
- Study dates
- 3 Jul 2018to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Man and woman age ≥ 18 years
- Francophone
- Patient with medical insurance
- Refraction: sphere ± 5.0 D and cylinder ± 3.0 D
- Pupillary diameter ≥ 3mm
- Early glaucoma patients :
Show all 14Show fewer
- Intraocular pressure> 21 mmHg or <21mmHg under treatment
- Thickness of pathological retinal nerve fibers with at least one affected area (OCT)
- At least one reliable visual field (false positives, false negatives and fixation losses ≤ 25%) and no artifacts, with Corrected Pattern Standard Deviation (CPSD) pathological in the 5% and Glaucoma Hemifield Pathological test and an early attack (MD> -6dB)
- Patient at risk for glaucoma with:
- And / or family history of glaucoma
- and / or intraocular pressure> 21 mmHg
- and / or retinal nerve fibers (pathological thickness in at least one area on the OCT)
- and / or reliable visual field (false positives, false negatives and fixation losses ≤ 25%) and without artifact, with pathological Corrected Pattern Standard Deviation (CPSD) in the 5% and Glaucoma Hemifield Pathological Test and an early onset (MD> -6 dB).
Who cannot join
- Visual acuity below 20/30 (Snellen scale or equivalent on another visual acuity scale)
- Unreliable visual field (false positives, loss of fixation and false negatives> 25%)
- History of intraocular surgery (except uncomplicated cataract surgery)
- Ocular pathology other than associated glaucoma
- Neurological disease affecting the visual field or the optic nerve
- History of macular laser or pan retinal photocoagulation
Show all 13Show fewer
- Unreliable ERGP pattern
- Offset OCT, unreliable
- Refusal to participate in the study
- Patient under tutorship or curatorship
- Patient deprived of liberty
- Epileptic patient
- Eczema of the eyelids or allergy to one of the components of the electrodes or skin gel allowing the cleaning of the skin before the positioning of the electrodes.
Trial locations and contacts
1 site in 1 country.
About this study
Glaucoma is a common and potentially blinding disease. It is characterized by an optic nerve damage, a visual field defect and elevated intraocular pressure (IOP).
The loss of retinal nerve fibers is accompanied by functional impairment in the territories corresponding to deficits of the visual field. However, this structure-function relationship is not always found initially. These discrepancies are mainly chronological: the structural damage preceding the functional impairment sometimes of several years
Read the detailed description
The electroretinogram pattern (ERGP) is an electrophysiological exploration technique that reflects the activity of retinal ganglion cells. It presents itself as an objective field of vision that does not require the active collaboration of the patient. It consists in recording the electrical activity of functional retinal ganglion cells following a light stimulation. Simple (30 minutes maximum), it could improve the detection of early forms of glaucoma. A significant ERGP is also thought to be correlated with peripapillary and macular CNP structural involvement of the ganglionic complex in early forms of glaucoma (MD> -6 dB).
Some results even suggest that ganglion dysfunction could be detected by the ERGP eight years on average before the occurrence of detectable alterations on the RNFL OCT. ERGP is already recognized as a routine examination for monitoring glaucomatous patients (review side in nomenclature and reimbursed by Social Security) but it could therefore be used as a diagnostic tool in very early forms of intraocular hypertonia glaucoma so to objectify signs of preperimetric functional impairment in order to establish a suitable hypotonizing treatment and to improve the prognosis of this disease.
- Conditions
- Glaucoma
- Being tested
- Electroretinogram Pattern (Diopsys® NOVA System)
- Keywords
- electroretinogram pattern
- Medical subject headings
- Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Electroretinogram Pattern (Diopsys® NOVA System)Device
it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes
| Study group | Role | What they receive |
|---|---|---|
| early age of glaucoma or with important risk factors | Experimental | All patients included will benefit from a complete ophtalmic examination including visual acuity, slit lamp biomicroscopic examination of the anterior segment, measurement of intraocular pressure by Goldmann tonometer aplanation, dynamic gonioscopy with Posner glass. They will also have a fundus examination with examination of the retina, macula and optic nerve as well as the ERGP. Receives: Device: Electroretinogram Pattern (Diopsys® NOVA System) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlations between Electroretinogram Pattern, vision field and optical coherence tomography
Electroretinogram Patterny : Magnitude, magnitude D, Magnitude D/Magnitude ratio.
Measured: Time of inclusion
Correlations between Electroretinogram Pattern, vision field and optical coherence
Vision field: mean deviation, corrected pattern standard deviation.
Measured: Time of inclusion
Correlations between Electroretinogram Pattern, vision field and optical coherence
Optical coherence tomography: retinal nerve fiber layer thickness and macular analysis of the ganglionic complex.
Measured: Time of inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Aug 2018
- Study start3 Jul 2018
- Primary completion2 Jul 2019
- Study completion31 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (24)Papers the sponsor has linked to this study.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fondation Hôpital Saint-Joseph
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03642782
- Sponsor's protocol ID
- DIOPSYS
- Acronym
- DIOPSYS
- Status last verified
- Apr 2023
- First submitted
- 13 Aug 2018
- Last updated
- 27 Apr 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30. doi: 10.1001/archopht.120.6.714.
PubMed 12049575Quigley HA, Dunkelberger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol. 1989 May 15;107(5):453-64. doi: 10.1016/0002-9394(89)90488-1.
PubMed 2712129Harwerth RS, Quigley HA. Visual field defects and retinal ganglion cell losses in patients with glaucoma. Arch Ophthalmol. 2006 Jun;124(6):853-9. doi: 10.1001/archopht.124.6.853.
PubMed 16769839Sommer A, Katz J, Quigley HA, Miller NR, Robin AL, Richter RC, Witt KA. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol. 1991 Jan;109(1):77-83. doi: 10.1001/archopht.1991.01080010079037.
PubMed 1987954Hwang YH, Kim YY, Kim HK, Sohn YH. Ability of cirrus high-definition spectral-domain optical coherence tomography clock-hour, deviation, and thickness maps in detecting photographic retinal nerve fiber layer abnormalities. Ophthalmology. 2013 Jul;120(7):1380-7. doi: 10.1016/j.ophtha.2012.12.048. Epub 2013 Mar 28.
PubMed 23541761Tan O, Chopra V, Lu AT, Schuman JS, Ishikawa H, Wollstein G, Varma R, Huang D. Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography. Ophthalmology. 2009 Dec;116(12):2305-14.e1-2. doi: 10.1016/j.ophtha.2009.05.025. Epub 2009 Sep 10.
PubMed 19744726Na JH, Lee K, Lee JR, Baek S, Yoo SJ, Kook MS. Detection of macular ganglion cell loss in preperimetric glaucoma patients with localized retinal nerve fibre defects by spectral-domain optical coherence tomography. Clin Exp Ophthalmol. 2013 Dec;41(9):870-80. doi: 10.1111/ceo.12142. Epub 2013 Jul 5.
PubMed 23777476Mwanza JC, Oakley JD, Budenz DL, Anderson DR; Cirrus Optical Coherence Tomography Normative Database Study Group. Ability of cirrus HD-OCT optic nerve head parameters to discriminate normal from glaucomatous eyes. Ophthalmology. 2011 Feb;118(2):241-8.e1. doi: 10.1016/j.ophtha.2010.06.036. Epub 2010 Oct 28.
PubMed 20920824Hwang YH, Kim YY. Glaucoma diagnostic ability of quadrant and clock-hour neuroretinal rim assessment using cirrus HD optical coherence tomography. Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2226-34. doi: 10.1167/iovs.11-8689.
PubMed 22410556De Jong LA, Snepvangers CE, van den Berg TJ, Langerhorst CT. Blue-yellow perimetry in the detection of early glaucomatous damage. Doc Ophthalmol. 1990 Oct;75(3-4):303-14. doi: 10.1007/BF00164844.
PubMed 2090405Felius J, de Jong LA, van den Berg TJ, Greve EL. Functional characteristics of blue-on-yellow perimetric thresholds in glaucoma. Invest Ophthalmol Vis Sci. 1995 Jul;36(8):1665-74.
PubMed 7601646Sample PA, Taylor JD, Martinez GA, Lusky M, Weinreb RN. Short-wavelength color visual fields in glaucoma suspects at risk. Am J Ophthalmol. 1993 Feb 15;115(2):225-33. doi: 10.1016/s0002-9394(14)73928-5.
PubMed 8430733Anderson AJ, Johnson CA. Frequency-doubling technology perimetry. Ophthalmol Clin North Am. 2003 Jun;16(2):213-25. doi: 10.1016/s0896-1549(03)00011-7.
PubMed 12809159Anderson AJ, Johnson CA, Fingeret M, Keltner JL, Spry PG, Wall M, Werner JS. Characteristics of the normative database for the Humphrey matrix perimeter. Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1540-8. doi: 10.1167/iovs.04-0968.
PubMed 15790927Artes PH, Hutchison DM, Nicolela MT, LeBlanc RP, Chauhan BC. Threshold and variability properties of matrix frequency-doubling technology and standard automated perimetry in glaucoma. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2451-7. doi: 10.1167/iovs.05-0135.
PubMed 15980235
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Electroretinogram Pattern (Diopsys® NOVA System) for the Early Diagnosis of Glaucoma
- ClinicalTrials.gov ID
- NCT03642782
- Acronym / sponsor ID
- DIOPSYS / DIOPSYS
- Conditions
- Glaucoma
- Keywords
- electroretinogram pattern
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Fondation Hôpital Saint-JosephUniversity, hospital or other
- Study start
- 3 Jul 2018 (actual)
- Primary completion
- 2 Jul 2019 (actual)
- Study completion
- 31 Dec 2023 (estimated)
- First posted
- 22 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Glaucoma is a common and potentially blinding disease. It is characterized by an optic nerve damage, a visual field defect and elevated intraocular pressure (IOP).
The loss of retinal nerve fibers is accompanied by functional impairment in the territories corresponding to deficits of the visual field. However, this structure-function relationship is not always found initially. These discrepancies are mainly chronological: the structural damage preceding the functional impairment sometimes of several years
Detailed description
The electroretinogram pattern (ERGP) is an electrophysiological exploration technique that reflects the activity of retinal ganglion cells. It presents itself as an objective field of vision that does not require the active collaboration of the patient. It consists in recording the electrical activity of functional retinal ganglion cells following a light stimulation. Simple (30 minutes maximum), it could improve the detection of early forms of glaucoma. A significant ERGP is also thought to be correlated with peripapillary and macular CNP structural involvement of the ganglionic complex in early forms of glaucoma (MD> -6 dB).
Some results even suggest that ganglion dysfunction could be detected by the ERGP eight years on average before the occurrence of detectable alterations on the RNFL OCT. ERGP is already recognized as a routine examination for monitoring glaucomatous patients (review side in nomenclature and reimbursed by Social Security) but it could therefore be used as a diagnostic tool in very early forms of intraocular hypertonia glaucoma so to objectify signs of preperimetric functional impairment in order to establish a suitable hypotonizing treatment and to improve the prognosis of this disease.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| early age of glaucoma or with important risk factors | Experimental | Device: Electroretinogram Pattern (Diopsys® NOVA System)All patients included will benefit from a complete ophtalmic examination including visual acuity, slit lamp biomicroscopic examination of the anterior segment, measurement of intraocular pressure by Goldmann tonometer aplanation, dynamic gonioscopy with Posner glass. They will also have a fundus examination with examination of the retina, macula and optic nerve as well as the ERGP. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Man and woman age ≥ 18 years
- Francophone
- Patient with medical insurance
- Refraction: sphere ± 5.0 D and cylinder ± 3.0 D
- Pupillary diameter ≥ 3mm
Key exclusion criteria (13 listed)
- Visual acuity below 20/30 (Snellen scale or equivalent on another visual acuity scale)
- Unreliable visual field (false positives, loss of fixation and false negatives> 25%)
- History of intraocular surgery (except uncomplicated cataract surgery)
- Ocular pathology other than associated glaucoma
- Neurological disease affecting the visual field or the optic nerve
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Electroretinogram Pattern (Diopsys® NOVA System)it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes | Device | early age of glaucoma or with important risk factors |
Primary outcome
Correlations between Electroretinogram Pattern, vision field and optical coherence tomography
Time frame: Time of inclusion
Electroretinogram Patterny : Magnitude, magnitude D, Magnitude D/Magnitude ratio.
Correlations between Electroretinogram Pattern, vision field and optical coherence
Time frame: Time of inclusion
Vision field: mean deviation, corrected pattern standard deviation.
Correlations between Electroretinogram Pattern, vision field and optical coherence
Time frame: Time of inclusion
Optical coherence tomography: retinal nerve fiber layer thickness and macular analysis of the ganglionic complex.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2023.
- Results publication: PubMed 12049575Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30. doi: 10.1001/archopht.120.6.714.
- Results publication: PubMed 2712129Quigley HA, Dunkelberger GR, Green WR. Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol. 1989 May 15;107(5):453-64. doi: 10.1016/0002-9394(89)90488-1.
- Results publication: PubMed 16769839Harwerth RS, Quigley HA. Visual field defects and retinal ganglion cell losses in patients with glaucoma. Arch Ophthalmol. 2006 Jun;124(6):853-9. doi: 10.1001/archopht.124.6.853.
- Results publication: PubMed 1987954Sommer A, Katz J, Quigley HA, Miller NR, Robin AL, Richter RC, Witt KA. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol. 1991 Jan;109(1):77-83. doi: 10.1001/archopht.1991.01080010079037.
- Results publication: PubMed 23541761Hwang YH, Kim YY, Kim HK, Sohn YH. Ability of cirrus high-definition spectral-domain optical coherence tomography clock-hour, deviation, and thickness maps in detecting photographic retinal nerve fiber layer abnormalities. Ophthalmology. 2013 Jul;120(7):1380-7. doi: 10.1016/j.ophtha.2012.12.048. Epub 2013 Mar 28.
- Results publication: PubMed 19744726Tan O, Chopra V, Lu AT, Schuman JS, Ishikawa H, Wollstein G, Varma R, Huang D. Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography. Ophthalmology. 2009 Dec;116(12):2305-14.e1-2. doi: 10.1016/j.ophtha.2009.05.025. Epub 2009 Sep 10.
- Results publication: PubMed 23777476Na JH, Lee K, Lee JR, Baek S, Yoo SJ, Kook MS. Detection of macular ganglion cell loss in preperimetric glaucoma patients with localized retinal nerve fibre defects by spectral-domain optical coherence tomography. Clin Exp Ophthalmol. 2013 Dec;41(9):870-80. doi: 10.1111/ceo.12142. Epub 2013 Jul 5.
- Results publication: PubMed 20920824Mwanza JC, Oakley JD, Budenz DL, Anderson DR; Cirrus Optical Coherence Tomography Normative Database Study Group. Ability of cirrus HD-OCT optic nerve head parameters to discriminate normal from glaucomatous eyes. Ophthalmology. 2011 Feb;118(2):241-8.e1. doi: 10.1016/j.ophtha.2010.06.036. Epub 2010 Oct 28.
- Results publication: PubMed 22410556Hwang YH, Kim YY. Glaucoma diagnostic ability of quadrant and clock-hour neuroretinal rim assessment using cirrus HD optical coherence tomography. Invest Ophthalmol Vis Sci. 2012 Apr 24;53(4):2226-34. doi: 10.1167/iovs.11-8689.
- Results publication: PubMed 2090405De Jong LA, Snepvangers CE, van den Berg TJ, Langerhorst CT. Blue-yellow perimetry in the detection of early glaucomatous damage. Doc Ophthalmol. 1990 Oct;75(3-4):303-14. doi: 10.1007/BF00164844.
- Results publication: PubMed 7601646Felius J, de Jong LA, van den Berg TJ, Greve EL. Functional characteristics of blue-on-yellow perimetric thresholds in glaucoma. Invest Ophthalmol Vis Sci. 1995 Jul;36(8):1665-74.
- Results publication: PubMed 8430733Sample PA, Taylor JD, Martinez GA, Lusky M, Weinreb RN. Short-wavelength color visual fields in glaucoma suspects at risk. Am J Ophthalmol. 1993 Feb 15;115(2):225-33. doi: 10.1016/s0002-9394(14)73928-5.
Related trials for Glaucoma
Not yet recruiting
PAUL® Glaucoma Implant Safety and Effectiveness Study
Refractory Glaucoma
Not yet recruiting
Glaucoma Drop Aids Part 2
Glaucoma, Intraocular Pressure
RecruitingObservational study
Anterior Segment Anatomy Assessed by Swept-Source OCT in Ocular Surgery Patients
Cataract, Primary Angle-Closure Glaucoma
Recruiting
The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project).
Glaucoma Open-Angle Primary, Hypertension
RecruitingObservational study
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
Primary Open Angle Glaucoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Electroretinogram Pattern (Diopsys® NOVA System) in people with Glaucoma, run by Fondation Hôpital Saint-Joseph at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 27 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlations between Electroretinogram Pattern, vision field and optical coherence tomography (time frame: Time of inclusion). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03642782, which also lists 24 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2023.